GGrantIndex
← Leaderboards

Glycot Therapeutics, Llc

Ellicott City, MD

Compare ↔
$5,616,858
Total funding
7
Grants

Funding over time

peak $977.8K · FY201725
$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,616,858 · 7

By mechanism

R44$4,483,950 · 3
R43$1,132,908 · 4

Investigators at Glycot Therapeutics, Llc

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Emerging Leaders

6–10 yrs in

Largest grants

Development of streamlined one-pot chemoenzymatic glycan remodeling systems for antibody conjugation$977,787
R44 · FY2025 · GM
Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins$774,934
R44 · FY2021 · GM
Development of streamlined one-pot chemoenzymatic glycan remodeling systems for antibody conjugation$758,302
R44 · FY2024 · GM
Chemoenzymatic Glycan Remodeling of IVIG for Improved Anti-inflammatory Activity$714,065
R44 · FY2019 · GM
Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins$713,666
R44 · FY2022 · GM
Chemoenzymatic Glycan Remodeling of IVIG for Improved Anti-inflammatory Activity$545,196
R44 · FY2020 · GM
Chemoenzymatic synthesis of stable isotope-labeled glycopeptides as internal standards for glycosylation quantitation$292,823
R43 · FY2018 · GM
Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation$231,535
R43 · FY2022 · GM
Chemoenzymatic glycan remodeling of IVIG for improved anti-inflammatory activity$218,846
R43 · FY2017 · GM
Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins$150,000
R43 · FY2019 · GM
Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins$150,000
R43 · FY2020 · GM
Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation$89,704
R43 · FY2023 · GM